1 / 16

A Molecular View of Phenylketonuria

A Molecular View of Phenylketonuria. By: Sindhu Kilakkathi. What is Phenylketonuria (PKU)?. Autosomal recessive genetic disorder (Incidence: 1/10,000 newborns) Mutation of Phenylalanine hydroxylase (PAH) gene on chromosome 12 1 Lack of PAH, defective PAH, insufficient BH 4. PAH.

noleta
Télécharger la présentation

A Molecular View of Phenylketonuria

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. A Molecular View of Phenylketonuria By: Sindhu Kilakkathi

  2. What is Phenylketonuria (PKU)? • Autosomal recessive genetic disorder (Incidence: 1/10,000 newborns) • Mutation of Phenylalanine hydroxylase (PAH) gene on chromosome 121 • Lack of PAH, defective PAH, insufficient BH4 PAH Phenylalanine Tyrosine BH4 Phe Normal PAH Tyrosine

  3. What is Phenylketonuria (PKU)? • Autosomal recessive genetic disorder (Incidence: 1/10,000 newborns) • Mutation of Phenylalanine hydroxylase (PAH) gene on chromosome 121 • Lack of PAH, defective PAH, insufficient BH4 PAH Phenylalanine Tyrosine BH4 Phe Mutated PAH Phe Metabolites Phe Metabolites Phe Metabolites Phe Metabolites Phe Metabolites

  4. Effects of PAH Enzymopathy • Accumulation of Phe elevated blood and urine Phe levels • Decreased levels of Tyr  lack of catecholamines (necessary for development) and melanin Melanin PAH TH Phenylalanine Tyrosine DOPA BH4 BH4 Catecholamines

  5. Symptoms of PKU • Severe mental retardation, brain damage, seizures, mousy odor in skin and hair, lack of pigmentation, eczema, IQ of <50, aggressive behavior, negative mood • Reduced dopamine levels • hypomyelination5 • Variability in expressivity • More prevalent in certain ethnic populations (e.g. Turkish- 1/2600)1 http://www.dshs.state.tx.us/newborn/over_pku.shtm

  6. Diagnosis • PKU first detected with FeCl3 test (phenylpyruvate + FeCl3 green urine)2 • Now Guthrie test is used (4 mg/dL) • Prenatal testing (DNA probes)1 http://www.flickr.com/photos/ozewiezewozewiezewallakristallix/2632833781/

  7. Implications for Carriers of PKU • 1.5% population are heterozygotes • Appear phenotypically normal, but have lower levels of PAH and higher blood levels of Phe • Definitive test: measure kinetics of disappearance of injected Phe2 ?

  8. Treatment • Low Phe diet started soon after birth (restricted protein and dairy consumption)3 • Supplements- BH4 (Kuvan and Phenoptin) • Phenylalanine ammonia lyase (enzyme substitution) • Gene therapy (viral vectors to introduce functional PAH gene into liver cells)1

  9. Understanding the Biochemistry of PKU • Root of the Problem: • Mutations in PAH [PDB ID: 2PAH] • Cause of the Symptoms: • Interaction of Phe with Large Neutral Amino Acids (LNAAs) at the Blood Brain Barrier (BBB) [PDB ID: 2DH2] • Treatment: • How PAL can treat PKU [PDB ID: 1Y2M]

  10. A Closer Look at PAH Tetramer Monomer Regulatory Domain 2 identical alpha subunits – cyan 2 identical beta subunits – red

  11. Mutations of PAH • 400+ mutations of PAH gene that cause PKU • Most frequent mutation- R408W • Tryptophan substituted for arginine

  12. An Examination of LNAAs • LNAA carriers transport LNAAs across BBB • LAT1 transporter encoded for by SLC3A2 and SLC3A5 genes in 4F2hc • 4F2hc (CD98hc)- multifunction type II membrane glycoprotein • Phe blocks transport of Tyr and Trp Acetone

  13. Treatment with PAL • Another enzyme that can catabolizePhe PAL Trans-cinnamic acid NH3 Phenylalanine

  14. PAL Structure Homotetrameric Overlap of the 4 subunits 4 identical monomers

  15. Issues with PAL in Treatment • Accessible PAL trypin and chymotrypsin cleavage sites- Arg123 and Tyr 110 • Conjugate with Polyethylene gycol (PEG) to increase efficacy • So far there have not been major side effects

  16. References • 1. Williams RA, Mamotte CD, Burnett JR. Phenylketonuria: an inborn error of phenylalanine metabolism. ClinBiochem Rev. 2008; 29(1):31-41. • 2. Berg, Jeremy Mark., John L. Tymoczko, and LubertStryer. Biochemistry. 6th ed. New York: W.H. Freeman, 2007. 673-74. Print. • 3. Michals-Matalon K. Developments in phenylketonuria. Topics ClinNutr. 2001;16:41–50. • 4. Dyer CA. Pathophysiology of phenylketonuria. Ment Retard Dev Disab Res Rev. 1999;5:104–12. • 5. Erlandsen H, Stevens RC. 1999. The structural basis of phenylketonuria. Mol Genet Metab 68: 103-125.

More Related